The rationale for blending these two peptides stems from their non-overlapping receptor targets and complementary metabolic effects: Amylin Pathway (Cagrilintide): Targets amylin receptors in the brainstem Creates meal-specific satiety signals Slows gastric emptying through distinct mechanisms Reduces meal size and eating frequency Triple Agonist Pathway (Retatrutide): Activates GIP, GLP-1, and glucagon receptors Enhances insulin secretion and glucose metabolism Increases energy expenditure through glucagon effects Provides broader metabolic regulation When combined, these pathways could theoretically provide additive or synergistic effects on weight management and metabolic function
On an ongoing month-to-month basis, PlexusDx Tirzepatide Injection at $289/mo carries the lowest ongoing rate in this comparison
Abdalla MA, Soyiri I, Atkin S, Sathyapalan T
Retatrutide may be suitable for adults who: Have a body mass index (BMI) of 27 or higher Struggle with weight management despite diet and exercise efforts Have type 2 diabetes Do not have a personal or family history of certain medical conditions or allergies Semaglutide may be suitable for adults who: Have a BMI of 30 or higher BMI of 27 or higher with weight-related conditions, such as type 2 diabetes, high blood pressure, or high cholesterol Struggle with weight management, mainly if youve had limited success with diet and exercise alone
